A boutique venture capital firm headquartered in Boston with a global outreach and epicenter in Dubai has invested alongside Tier 1 VCs in 12 companies with 5 exits qualified as unicorns. The firm is stage-agnostic and can invest at any stage. With this said, check sizes are flexible and can range from $500K – $15M. Their capital comes mostly from qualified purchasers (investors) located in the MENA region at large and GCC region specifically. To date, the firm has invested in USA based companies.
The firm is focused on healthcare, energy, ICT and infotech and most recently data defined networks addressing the systems aging and longevity (and research at large) pain points. The firm has invested in medi-tech, health-tech and biotech in the past which includes but not limited to diagnostics, medical devices, therapeutics, and digital health. The firm invests within 4 pillars of longevity roadmap covering health span and lifespan namely: (a) preventative, (b) replacement, (c) biostasis, and (d) therapeutics and genetic engineering on the basis that they are targeting systems aging and longevity. The firm prefers a management team with domain expertise, past performance and PhD’s / higher educational pedigree.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.






Max Braht, Business Development Manager, Life Science Nation | Diana Caldwell, MBA,CEO and Co-Founder, Amplified Sciences | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Greg Mannix, VP, International Business Development, Life Science Nation | Victoria Costa Paz, CEO and Co-Founder, EYWA Biotech | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Momo Yamamoto, Investor Research Analyst, Life Science Nation | John Qiao, Founder and CEO, RadioClash | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

The Soft-Landing program, held at the Cambridge Innovation Center (CIC), offered an insightful look into how international companies can effectively establish a foothold in the U.S. life science market, with a focus on the Boston-Cambridge area—one of the world’s most significant hubs for life sciences. The event attracted over 100 registrants interested in commencing operations in the region. The CIC, which also presented during the event, provided an ideal backdrop as a key hub for regional innovation and collaboration.



